## Elisa Porcellini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9092045/publications.pdf

Version: 2024-02-01

55 6,838 25 53 g-index

56 56 56 56 9869

docs citations

all docs

times ranked

citing authors

#	Article	IF	CITATIONS
1	Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1094-1099.	21.4	2,155
2	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	21.4	1,708
3	APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Molecular Psychiatry, 2011, 16, 903-907.	7.9	529
4	Homocysteine and folate as risk factors for dementia and Alzheimer disease. American Journal of Clinical Nutrition, 2005, 82, 636-643.	4.7	386
5	Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immunity and Ageing, 2005, 2, 8.	4.2	378
6	Homocysteine and folate as risk factors for dementia and Alzheimer disease. American Journal of Clinical Nutrition, 2005, 82, 636-643.	4.7	339
7	Herpes virus in Alzheimer's disease: relation to progression of the disease. Neurobiology of Aging, 2014, 35, 122-129.	3.1	148
8	Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiology of Aging, 2011, 32, 756.e11-756.e15.	3.1	82
9	Genetic risk profiles for Alzheimer's disease: Integration of APOE genotype and variants that up-regulate inflammation. Neurobiology of Aging, 2007, 28, 1637-1643.	3.1	67
10	Alzheimer's disease gene signature says: beware of brain viral infections. Immunity and Ageing, 2010, 7, 16.	4.2	65
11	Interleukin-6 gene polymorphism is an age-dependent risk factor for myocardial infarction in men. International Journal of Immunogenetics, 2005, 32, 349-353.	1.8	55
12	The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. Journal of Alzheimer's Disease, 2010, 22, 247-255.	2.6	54
13	Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications. Cancer Letters, 2018, 419, 84-95.	7.2	52
14	Genetic factors regulating inflammation and DNA methylation associated with prostate cancer. Prostate Cancer and Prostatic Diseases, 2013, 16, 56-61.	3.9	40
15	Elevated Plasma Levels of & Samp; #945; -1-Anti-Chymotrypsin in Age-Related Cognitive Decline and Alzheimers Disease: A Potential Therapeutic Target. Current Pharmaceutical Design, 2008, 14, 2659-2664.	1.9	39
16	Multivariable network associated with cognitive decline and dementia. Neurobiology of Aging, 2010, 31, 257-269.	3.1	37
17	A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease. Neurobiology of Aging, 2005, 26, 449-453.	3.1	36
18	Does Down's syndrome support the homocysteine theory of atherogenesis?. Archives of Gerontology and Geriatrics, 2006, 43, 381-387.	3.0	36

#	Article	IF	Citations
19	Peripheral Inflammatory Markers and Antioxidant Response during the Post-Acute and Chronic Phase after Severe Traumatic Brain Injury. Frontiers in Neurology, 2016, 7, 189.	2.4	36
20	Peripheral leukocyte expression of the potential biomarker proteins Bdnf, Sirt1, and Psen1 is not regulated by promoter methylation in Alzheimer's disease patients. Neuroscience Letters, 2015, 605, 44-48.	2.1	32
21	Gene Signature in Alzheimer's Disease and Environmental Factors: The Virus Chronicle. Journal of Alzheimer's Disease, 2011, 27, 809-817.	2.6	31
22	Reduced plasma levels of P-selectin and L-selectin in a pilot study from Alzheimer disease: relationship with neuro-degeneration. Biogerontology, 2011, 12, 451-454.	3.9	31
23	The 21st century epidemic: infections as inductors of neuro-degeneration associated with Alzheimer's Disease. Immunity and Ageing, 2014, 11, 22.	4.2	30
24	Interplay between small and long non oding <scp>RNA</scp> s in cutaneous melanoma: a complex jigsaw puzzle with missing pieces. Molecular Oncology, 2019, 13, 74-98.	4.6	29
25	Variations in inflammatory genes are associated with periodontitis. Immunity and Ageing, 2013, 10, 39.	4.2	27
26	The hydroxy-methyl-glutaryl CoA reductase promoter polymorphism is associated with Alzheimer's risk and cognitive deterioration. Neuroscience Letters, 2007, 416, 66-70.	2.1	26
27	Tumor Necrosis Factor-Alpha Antagonists: Differential Clinical Effects by Different Biotechnological Molecules. International Journal of Immunopathology and Pharmacology, 2009, 22, 567-572.	2.1	25
28	Sharing Pathogenetic Mechanisms between Acute Myocardial Infarction and Alzheimer's Disease as Shown by Partially Overlapping of Gene Variant Profiles. Journal of Alzheimer's Disease, 2011, 23, 421-431.	2.6	25
29	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591988554.	3.2	25
30	Pro-inflammatory genetic profile and familiarity of acute myocardial infarction. Immunity and Ageing, 2012, 9, 14.	4.2	23
31	Persistent infections, immune-senescence and Alzheimer's disease. Oncoscience, 2016, 3, 135-142.	2.2	22
32	Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2017, 18, 1547.	4.1	21
33	Gene-Gene and Gene-Clinical Factors Interaction in Acute Myocardial Infarction: A New Detailed Risk Chart. Current Pharmaceutical Design, 2010, 16, 783-788.	1.9	19
34	Monocyte chemoattractant protein-1 promoter polymorphism and plasma levels in alzheimer's disease. Immunity and Ageing, 2013, 10, 6.	4.2	18
35	Variants in Antiviral Genes are Risk Factors for Cognitive Decline and Dementia. Journal of Alzheimer's Disease, 2015, 46, 655-663.	2.6	15
36	Cancer Site-Specific Multiple microRNA Quantification by Droplet Digital PCR. Frontiers in Oncology, 2018, 8, 447.	2.8	15

3

#	Article	IF	CITATIONS
37	Defining the Prognostic Role of MicroRNAs in Cutaneous Melanoma. Journal of Investigative Dermatology, 2020, 140, 2260-2267.	0.7	15
38	Activation of Endogenous Retrovirus, Brain Infections and Environmental Insults in Neurodegeneration and Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 7263.	4.1	15
39	MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary. Molecular Oncology, 2021, 15, 2732-2751.	4.6	14
40	The G51S purine nucleoside phosphorylase polymorphism is associated with cognitive decline in Alzheimer's disease patients. Human Psychopharmacology, 2007, 22, 75-80.	1.5	13
41	Multi factorial interactions in the pathogenesis pathway of Alzheimer's disease: a new risk charts for prevention of dementia. Immunity and Ageing, 2010, 7, S4.	4.2	13
42	Impaired Innate Immunity Mechanisms in the Brain of Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 1126.	4.1	13
43	Unraveling the role of microRNA/isomiR network in multiple primary melanoma pathogenesis. Cell Death and Disease, 2021, 12, 473.	6.3	13
44	Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches. Frontiers in Cell and Developmental Biology, 2021, 9, 666156.	3.7	12
45	Altered Vessel Signalling Molecules in Subjects with Down's Syndrome. International Journal of Immunopathology and Pharmacology, 2006, 19, 205873920601900.	2.1	11
46	Impaired regulation of immune responses in cognitive decline and Alzheimer's disease: lessons from genetic association studies. Expert Review of Neurotherapeutics, 2006, 6, 1327-1336.	2.8	11
47	Polymorphisms of Fas Gene: Relationship with Alzheimer's Disease and Cognitive Decline. Dementia and Geriatric Cognitive Disorders, 2006, 22, 296-300.	1.5	11
48	Altered glycosylation profile of purified plasma ACT from Alzheimer's disease. Immunity and Ageing, 2010, 7, S6.	4.2	11
49	SHIP2: A "NEW―Insulin Pathway Target for Aging Research. Rejuvenation Research, 2014, 17, 221-225.	1.8	9
50	Serum neutrophil gelatinase-B associated lipocalin (NGAL) levels in Down's syndrome patients. Immunity and Ageing, 2010, 7, S7.	4.2	7
51	Role of prothrombotic polymorphisms in successful or unsuccessful aging. Biogerontology, 2011, 12, 445-450.	3.9	7
52	Haplotype of Single Nucleotide Polymorphisms in Exon 6 of the MZF-1 Gene and Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 34, 439-447.	2.6	5
53	Neopterin Levels and Immune Activation in the Blood of Children with Down's Syndrome. Pteridines, 2005, 16, 35-39.	0.5	1
54	A New Risk Chart for Acute Myocardial Infarction by a Innovative Algoritm., 2015,,.		1

#	Article	IF	CITATIONS
55	A New Risk Chart of Acute Myocardial Infarction in Men by an Innovative Algorithm: A Pilot Study. Current Pharmacogenomics and Personalized Medicine, 2015, 12, 159-166.	0.2	0